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ABSTRACT
Introduction Clopidogrel is an antiplatelet agent that is 
widely used for the secondary prevention of cardiovascular 
and cerebrovascular events. The genotype of cytochrome 
P450 2C19 (CYP2C19) differentially affects the liver’s 
metabolism of clopidogrel, which may influence the drug’s 
response and efficacy for cardiovascular event prevention. 
In contrast to prior studies of patients with coronary artery 
diseases, little is known about whether the CYP2C19 
genotype influences the preventive efficacy of clopidogrel 
in patients who had a stroke. We hypothesise that, among 
patients who had an acute ischaemic stroke who are 
prescribed clopidogrel, the patients with a loss- of- function 
CYP2C19 genotype (poor and intermediate metabolisers) 
may be at a higher risk of composite cardiovascular events 
than those who are non- carriers (extensive metabolisers).
Methods and analysis This prospective observational 
multicentre study was designed to determine whether 
composite cardiovascular events would differ among 
patients who had an ischaemic stroke prescribed 
clopidogrel according to CYP2C19 genotype (poor or 
intermediate vs extensive metabolisers). Inclusion criteria 
were patients who had an acute ischaemic stroke who 
underwent CYP2C19 genotype evaluation and received 
clopidogrel within 72 hours of stroke onset. The primary 
outcome is composite cardiovascular events (stroke, 
myocardial infarction, or cardiovascular death) within 6 
months after acute ischaemic stroke between patients 
categorised as poor or intermediate metabolisers and 
those categorised as extensive metabolisers according to 
their CYP2C19 genotype.
Ethics and dissemination The Institutional Review 
Board of Severance Hospital, Yonsei University College of 
Medicine approved this study (3-2019-0195). We received 
study approval from the institutional review board of each 
participating hospital. We plan to disseminate our findings 
at relevant conferences and meetings and through peer- 
reviewed journals.
Trial registration number NCT04072705.
INTRODUCTION
Clopidogrel is an antiplatelet agent used 
as a secondary prevention in patients who 
had an ischaemic stroke, coronary artery 
disease and peripheral artery disease.1–4 
Clopidogrel exhibits antithrombotic effects 
by inhibiting platelet aggregation via P2Y12 
(an adenosine diphosphate receptor on the 
platelets) by active metabolites that have 
undergone metabolism in the liver.5 In asso-
ciation with the metabolic pathway, there has 
been concern about the problem of clopido-
grel resistance. The administration of drugs 
including atorvastatin or omeprazole that are 
subjected to the same metabolic processes 
as clopidogrel may cause inhibitory interac-
tions.6 7
Moreover, studies have shown that the geno-
type of cytochrome P450 2C19 (CYP2C19), an 
enzyme involved in the liver metabolism of 
clopidogrel, affects drug responses and recur-
rence rates of cardiovascular disease. Among 
persons treated with clopidogrel, carriers of a 
loss- of- function CYP2C19 allele (poor or inter-
mediate metabolisers) had significantly lower 
levels of the active metabolite of clopidogrel, 
decreased platelet inhibition and a higher 
rate of major adverse cardiovascular events, 
including stent thrombosis, than did non- 
carriers (extensive metabolisers).8 In patients 
with acute myocardial infarction receiving 
Strengths and limitations of this study
 ► This study will include a large sample size of pa-
tients who had an acute ischaemic stroke who re-
ceived clopidogrel within 3 days after stroke onset.
 ► It will address the controversy of clopidogrel resis-
tance according to CYP2C19 genotype in the sec-
ondary prevention of acute ischaemic stroke.
 ► The *2, *3 alleles of the CYP2C19 gene are relatively 
common in Asian populations; thus, the study sam-
ple size can be reduced.
 ► Our findings may not be widely generalisable since 
the study participants will all be Asian.
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clopidogrel, particularly those who received percuta-
neous coronary intervention, patients who were CYP2C19 
loss- of- function allele carriers had a higher rate of subse-
quent cardiovascular events than those who were not.9 
Among patients with transient ischaemic attack or minor 
stroke, the use of both aspirin and clopidogrel compared 
with aspirin alone reduced the risk of recurrent stroke 
only in the subgroup of patients who were loss- of- function 
CYP2C19 allele non- carriers.10 In patients who had a small 
subcortical stroke, intermediate or poor metabolisers of 
clopidogrel had higher odds of recurrent stroke than 
extensive metabolisers in western populations.11 However, 
these studies were post- hoc analyses of patients who had a 
minor stroke or lacunar stroke subtypes. Prospective trials 
to date using large sample sizes to determine whether 
major cardiovascular events, including stroke, according 
to CYP2C19 genotype in patients who had an acute isch-
aemic stroke are limited.12 In addition, studies of the asso-
ciation between the CYP2C19 genotype and future major 
cardiovascular events in patients who had a stroke are 
lacking in the real- world practice setting.
We hypothesise that, among patients who had an 
acute ischaemic stroke who are prescribed clopidogrel, 
those carrying the loss- of- function CYP2C19 allele (poor 
and intermediate metabolisers) will be at higher risk 
of composite cardiovascular events including stroke, 
myocardial infarction and cardiovascular death than 
non- carriers (extensive metabolisers). To prove our 
hypothesis, we will perform the multicentre Prospective 
observationaL study to evAluate the effecT of clopidogrel 
on the prEvention of major vascuLar events according 
to the gEnotype of cytochrome P450 2C19 in ischemic 
stroke paTients (PLATELET) trial.
METHODS AND ANALYSIS
Study aims
We aim to provide evidence to support our hypothesis 
that patients with poor or intermediate metaboliser 
CYP2C19 genotypes are more likely to present with the 
occurrence of composite cardiovascular events, including 
stroke, myocardial infarction and cardiovascular death, 
than those with extensive metaboliser CYP2C19 genotypes 
among patients who had an acute ischaemic stroke who 
received clopidogrel. The aims of this study are as follows.
Aim 1
Evaluate any difference in the incidence of composite 
cardiovascular events (stroke, myocardial infarction and 
cardiovascular death) between patients categorised as 
poor or intermediate metabolisers and those categorised 
as extensive metabolisers according to their CYP2C19 
genotype.
Aim 2
Evaluate any difference in the development of ischaemic 
stroke, transient ischaemic attack, myocardial infarction, 
revascularisation (cerebrovascular, coronary, aorta and 
peripheral artery), deterioration of early neurological 
symptoms, or modified Rankin scale score (0–2) at 3 
months after the index stroke between poor or interme-
diate metabolisers and extensive metabolisers according 
to CYP2C19 genotype.
Aim 3
Evaluate any difference in the incidence of all- cause 
mortality and bleeding events between poor or interme-
diate metabolisers and extensive metabolisers according 
to CYP2C19 genotype.
Subjects and dataset
This prospective observational multicentre study is 
designed to determine whether there are differences 
in composite cardiovascular events (stroke, myocardial 
infarction and cardiovascular death) in patients who had 
an ischaemic stroke according to CYP2C19 genotype. We 
will include patients who had an acute ischaemic stroke 
who received clopidogrel (75–300 mg) within 72 hours 
from stroke onset and underwent CYP2C19 genotype 
evaluation. Patients who meet the inclusion criteria will 
be included in the study after the researcher has fully 
explained the plan and obtained written consent from 
them and/or their kin. In this study, the timing of the 
index stroke will be based on the first appearance of 
neurological abnormalities associated with it. However, 
in cases in which a patient wakes up and discovers a 
neurological abnormality or when it is difficult to know 
the exact time at which the neurological symptoms first 
occurred, the last time that the patient was neurologically 
normal will be defined as the timing of the index stroke. 
Because this is an observational and not randomised 
study, there are no restrictions on clopidogrel administra-
tion mode. However, coadministration with antiplatelet 
agents other than aspirin and clopidogrel will be limited, 
and the clopidogrel will be maintained until the end of 
the study. Subjects will be visited at 1, 3 and 6 months 
after the start of clopidogrel to check for the occurrence 
of cardiovascular events and adverse reactions.
Inclusion/exclusion criteria
From September 2019 to December 2022, we will include 
patients who meet the following inclusion criteria: (1) 
received confirmation of ischaemic stroke on brain 
computed tomography (CT) or magnetic resonance 
image (MRI); (2) received clopidogrel within 72 hours 
after ischaemic stroke; (3) age older than 19 years; (4) 
having agreed to participate in the study within 7 days 
after ischaemic stroke; and (5) underwent CYP2C19 geno-
typing. We will exclude patients who meet the following 
exclusion criteria: (1) taking oral anticoagulants at the 
time of screening or scheduled to take medication within 
6 months; (2) require administration of antiplatelet 
agents other than aspirin and clopidogrel; (3) history of 
taking clopidogrel within 1 week prior to the index isch-
aemic stroke; (4) scheduled for coronary angioplasty and 
stent insertion, coronary artery bypass grafting, carotid 
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endarterectomy and cerebral artery stent implantation 
within 6 months; (5) diagnosis of severe concomitant 
disease with an expected life span of less than 2 years or 
a malignant tumour that has not been cured; (6) having 
participated in another drug trial within the previous 
30 days; (7) having findings corresponding to high- risk 
factors among the causes of cardiac embolism according 
to Trial of Org 10172 in Acute Stroke Treatment (TOAST) 
classification13; and (8) expected to have difficulty partic-
ipating in this study and continuing according to the 
researcher’s judgement.
Measures and observation variables
Table 1 lists the information, variables and parameters 
that should be checked during screening, at the three 
follow- up visits, and during unexpected visits. We will 
collect medical information about the following vari-
ables and parameters. At screening, written consent; 
date written consent was provided; subject identification 
number; demographic information (date of birth, sex, 
height, weight, body mass index); smoking status (packs/
year); history of hypertension, diabetes, dyslipidaemia, 
atrial fibrillation, coronary artery disease (myocardial 
infarction, unstable angina, percutaneous coronary 
artery intervention and coronary artery bypass surgery), 
stroke (transient ischaemic attack, cerebral infarction, 
cerebral haemorrhage, stroke not distinguished between 
cerebral infarction and cerebral haemorrhage), or malig-
nancy; and information about the index stroke (timing of 
index stroke, hospital visit date, and date of first dose of 
clopidogrel after index stroke) will be collected.
We will determine CYP2C19 genotypes (*1, *2, *3 and 
*17 alleles). We will then define extensive metabolisers 
as patients with *1/*1, *1/*17, *17/*17 genotypes, inter-
mediate metabolisers as patients with only one *2 or 
*3 genotypes (*1/*2, *1/*3, *2/*17 and *3/*17), and 
poor metabolisers as patients with only *2 or *3 geno-
types (*2/*2, *2/*3 and *3/*3).14 15 In our study, the *1 
CYP2C19 genotype will be applied if the patients do not 
test positive for any of the other alleles.
We will acquire vital signs and routine blood labora-
tory test results. Information on medication history and 
concomitant medication after the index stroke (anti-
platelet, antihypertensive, oral hypoglycaemic agents, 
insulin or lipid- lowering agents) will be obtained. More-
over, data will be collected regarding any thrombolytic 
therapies received (intravenous and/or intra- arterial), 
dose of clopidogrel and/or aspirin, admission date, 
discharge date, discharge paths (other departments, self- 
discharge, transferred to another hospital or death). We 
will also collect data on what kind of brain imaging, brain 
vessel imaging and cardiac tests are used to determine the 
TOAST classification.
Outcome measures
The primary outcome measure of our study will be a 
difference in the incidence of composite cardiovascular 
events (stroke, myocardial infarction or cardiovascular 
death) within 6 months after acute ischaemic stroke 
between patients categorised as poor or intermediate 
metabolisers and those categorised as extensive metabo-
lisers according to their CYP2C19 genotype. After enrol-
ment, patients will be followed up at 1 month (visit 1), 3 
months (visit 2) and 6 months (visit 3).
Recurrent stroke is defined as newly developed neuro-
logical symptoms lasting at least 24 hours or symptoms 
lasting less than 24 hours with relevant lesions visible 
on brain imaging after the index stroke.16 Myocardial 
infarction is defined as clinical evidence of acute myocar-
dial ischaemia and the detection of a rise and/or fall 
of cardiac troponin values with at least 1 value above 
the 99th percentile of the upper reference limit and 
at least one of the following: (1) symptoms of myocar-
dial ischaemia; (2) new ischaemic electrocardiography 
changes; (3) development of pathological Q waves; (4) 
imaging evidence of new loss of viable myocardium or 
new regional wall motion abnormality in a pattern consis-
tent with an ischaemic aetiology; or (5) identification of 
a coronary thrombus on angiography.17 Cardiovascular 
death is defined as a case of fatal stroke, fatal myocardial 
infarction or sudden death not clearly identified as being 
of non- vascular cause.
The secondary outcome measure of our study is to inves-
tigate whether there is a difference in the development of 
ischaemic stroke, transient ischaemic attack without isch-
aemic lesions on brain imaging, myocardial infarction, 
revascularisation (cerebrovascular, coronary, aorta and 
peripheral artery), deterioration of early neurological 
symptoms (when the total National Institutes of Health 
Stroke Scale score increases by 2 or more within 7 days 
of symptom onset), or the ratio of modified Rankin scale 
0–2 at 3 months after the index stroke between patients 
categorised as poor or intermediate metabolisers and 
those categorised as extensive metabolisers according to 
their CYP2C19 genotype.
The tertiary outcome, including safety outcome, if the 
presence or absence of a difference in the incidence of 
all- cause mortality, fatal bleeding, symptomatic cerebral 
haemorrhage, ocular bleeding, bleeding requiring more 
than two packs of whole blood or red blood cells, and 
bleeding requiring hospitalisation between patients cate-
gorised as poor or intermediate metabolisers and those 
categorised as extensive metabolisers according to their 
CYP2C19 genotype.
Data management and oversight
All outcomes generated during the study will be reported 
to the steering committee, which will review the reported 
events and confirm whether they meet the definition of 
outcomes. Data can be requested from each investigator 
for an accurate decision. In addition, a steering committee 
meeting will be held every 6 months to review the study 
progress and resolve any issues arising. Other occasional 
meetings may be held at the members’ request.
The anonymised research database for this study will 
be administered by the independent clinical research 
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organiser. The study data will be stored on an encrypted 
website and only be accessible by the study researchers. 
Data monitoring will be independently performed by 
the sponsor without any competing interests. The site 
investigators will take responsibility for the data moni-
toring and conduct of the PLATELET trial. At each site, 
eligibility, protocol violations and participant outcomes 
will also be reported. Four clinical research associates 
Table 1 Protocol of Prospective observationaL study to evAluate the effecT of clopidogrel on the prEvention of major 
vascuLar events according to the gEnotype of cytochrome P450 2C19 in ischemic stroke paTients study
Period Follow- up visit or telephone interview
Visit
Screening











  Inclusion/exclusion criteria‡ Informed consent‡ O
  Demographics§ O
  Vital sign¶ O O O O
  Smoking status** O O O O
  Medical history** O
  Information of index stroke** O
  TOAST classification** O
  Laboratory findings†† O
  CYP2C19 genotype†† O
  Brain image‡‡ O
  Cardiac evaluation§§ O
  NIHSS¶¶ O
  mRS*** O O O O
  Determination of whether to continue the study or to leave O O O
  History of antiplatelet medication††† O O O O
  Thrombolytic therapy‡‡‡ O
  Prior/concomitant medication§§§ O O O O
  Medical records of admission and discharge¶¶¶ O
  Occurrence of outcomes O O O
  Adverse event**** O O O
*Registration for the subject by confirming whether the final inclusion/exclusion criteria are met through the data collected at the screening visit.
†At case of early termination, we identify the reason for termination and perform the investigation as visit 3.
‡A written informed consent will be obtained from the subject prior to starting this trial.
§Collection for date of birth, sex, height, weight and body mass index at the screening visit.
¶Vital signs will be collected each visit for blood pressure and pulse.
**We will check smoking history at screening, and then check smoking status at follow- up visits (visits 1–3). At screening, we will identify the history of the following 
diseases (hypertension, diabetes, hyperlipidaemia, atrial fibrillation, coronary artery disease (myocardial infarction, unstable angina, percutaneous coronary 
intervention, coronary artery bypass surgery), transient ischaemic attack, cerebral infarction, cerebral haemorrhage, stroke not identified with cerebral infarction/
haemorrhage and cancer). Stroke subtype will be investigated.
††Laboratory test collection items are as follows (white cell count, neutrophil count, lymphocyte count, haemoglobin, haematocrit, platelet count, red blood cell 
distribution width, mean platelet volume, glucose (initial, fasting), blood urea nitrogen, creatinine, estimated glomerular filtration rate, liver panel, haemoglobin A1c, 
lipid panel, C- reactive protein, activated partial thromboplastin time, international normalised ratio, D- dimer, platelet drug response assay (VerifyNow P2Y12 reaction 
units test) and CYP2C19 genotype. Laboratory tests, CYP2C19 genotype and ECG collect the results of tests performed after index stroke.
‡‡We check the results of brain image (MRI, magnetic resonance angiography, CT, computed tomography angiography and digital subtraction angiograph). Brain 
image data use results that are performed after index ischaemic stroke and before visit 1.
§§For evaluation of potential cardiac source of embolism, we will investigate and acquire the results of electrocardiography (ECG), cardiac echocardiography and 
Holter examination.
¶¶We collect the National Institute of Health Stroke Scale (NIHSS) on every day during the hospitalisation period, from the date of hospitalisation to 7 days or to 
discharge day if patients discharge from hospital within 7 days.
***At screening, we collect two types of modified Rankin scale (mRS), prestroke mRS (baseline mRS) and mRS at discharge. If the patient was discharged from visit 
1 or later, the mRS at discharge was not required.
†††We will check whether antiplatelets are taken before prior index stroke and then the dose of clopidogrel, aspirin at follow- up visits.
‡‡‡At screening, we check for whether intravenous and/or intra- arterial thrombolysis was performed.
§§§Information of prestroke medications will be collected only at screening. The collection criteria for prestroke and concomitant medications are as follows: 
prestroke medications: antiplatelet, oral anticoagulant, antihypertensive agents, oral diabetes mellitus medications, insulin and statins which are taken within 1 week 
prior to index stroke; concomitant medications: antiplatelet, antihypertensive agents, oral diabetes mellitus medications, insulin, statins and statins which are taken 
after index stroke.
¶¶¶The admission record identifies the date of admission, the date of discharge and the route of discharge.
****In this study, only serious adverse events are collected.
CTA, computed tomography angiography; DSA, digital subtraction angiography; HbA1c, haemoglobin A1c; MRA, magnetic resonance angiography; TOAST, Trial of 
Org 10172 in Acute Stroke Treatment.
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are responsible for 36 institutions. Each site will be moni-
tored at least twice including an initial visit by the clin-
ical research associates. During the entire study period, a 
system query will occur using electronic case report forms 
and checked by the responsible clinical research associ-
ates. The site principal investigator will be responsible for 
documenting the occurrence of outcomes and reporting 
serious adverse events to the institutional review board of 
each site.
Sample size and statistical power
In the Clopidogrel versus Aspirin in Patients at Risk of 
Ischaemic Events study of patients who had recent isch-
aemic stroke, recent myocardial infarction or symptom-
atic peripheral arterial disease, the event rate per year 
of the composite outcomes including ischaemic stroke, 
myocardial infarction or cardiovascular death was 5.32% 
among patients who took clopidogrel (7.15% for the 
subgroup with recent ischaemic stroke).4 A meta- analysis 
comparing the risks according to the distribution of 
CYP2C19 genotypes in patients with acute cerebral infarc-
tion and transient ischaemia showed the risk of combined 
cardiovascular disease in the poor and intermediate 
metaboliser groups was about 1.51 times higher than 
that of the extensive metaboliser group.18 Considering 
the existing evidence in Korea regarding the distribu-
tion of CYP2C19 genotypes, it is estimated that poor and 
intermediate metabolisers account for 60% of the total 
population, while extensive metabolisers comprise the 
remaining 40%.19
Regarding our study’s primary outcome, the incidence 
of composite cardiovascular events (stroke, myocardial 
infarction and cardiovascular death) during the 6 months 
after index stroke are set at 3% in the extensive metab-
oliser group and 4.5% in the poor and intermediate 
metaboliser groups. Considering the number of subjects 
needed to test the hypothesis that the event- free survival 
of both groups is the same at the 6- month follow- up using 
the log- rank test (two- tailed test, alpha=0.05 and 1- beta 
(power)=0.80), 2634 participants are required (1581 
poor and intermediate metabolisers and 1053 extensive 
metabolisers). After the adjustment for an expected 10% 
dropout rate, a total of 2927 subjects are required. Thus, 
this study will enrol a total of 2927 patients who had an 
ischaemic stroke that developed within 72 hours of the 
first symptom onset.
Statistical analysis
To summarise the data, we will demonstrate the descrip-
tive statistics expressed as numbers with proportions for 
categorical variables and means with standard deviation 
or medians with interquartile ranges for continuous vari-
ables. To analyse the difference in baseline characteristics 
between the poor and intermediate metabolisers and the 
extensive metabolisers, the χ2 test, independent t- test and 
Mann- Whitney U- test are used for categorical variables, 
normally distributed continuous variables, and non- 
normally distributed continuous variables, respectively. 
The primary outcome of this study is the risk of devel-
oping composite cardiovascular events within 6 months. 
We will illustrate a Kaplan- Meier curve for the primary 
outcome and evaluate differences by CYP2C19 genotypes 
using the log- rank test.
To estimate the relative risk of each group, we will calcu-
late the HRs and 95% CIs of the study outcomes using 
univariate and multivariate Cox proportional hazard 
regression models. In the multivariate model, adjust-
ments will be made for sex, age and covariates (smoking, 
medical history, TOAST classification, National Institute 
of Health Stroke Scale (NIHSS) score, medication use 
and thrombolytic therapy) with values of p<0.1 in the 
univariate model. We will evaluate the differences in risks 
for the secondary and tertiary outcomes according to the 
CYP2C19 genotypes. Subgroup analyses will be performed 
by sex, individual CYP2C19 genotype, daily dose of clopi-
dogrel, concurrent use of aspirin, initial stroke severity 
(NIHSS score) and TOAST classification.
Patient and public involvement
No patients or citizens were involved in the development 
of the research question. No patient advisers will be 
included in this research project.
DISCUSSION
The findings of studies on whether cardiovascular 
outcomes differ by CYP2C19 genotype in patients who 
had an stroke remain controversial. Previous studies 
demonstrated that reduced or lost CYP2C19 function 
was associated with poorer outcomes and an increased 
risk of recurrent stroke in patients who had an isch-
aemic stroke.20 21 In contrast, no significant association of 
CYP2C19 status with future ischaemic events was found 
in patients who had an ischaemic stroke.22 In the overall 
cohort of the Secondary Prevention of Small Subcortical 
Strokes study, there were no differences in stroke recur-
rence according to CYP2C19 metaboliser status.11 In a 
meta- analysis, carriers of CYP2C19 loss- of- function alleles 
(*2, *3 and *8) were at a 1.92- times increased risk of 
stroke compared with non- carriers.18 Composite vascular 
events were also more frequent (1.51 times higher) in 
carriers of CYP2C19 loss- of- function alleles than in non- 
carriers among patients who had an ischaemic stroke or 
transient ischaemic attack treated with clopidogrel.18 Our 
study will provide information about the risk of composite 
cardiovascular events, including stroke, myocardial 
infarction and cardiovascular death, in patients who had 
an ischaemic stroke treated with clopidogrel and eluci-
date whether there are differences in early neurological 
deterioration, functional outcomes and bleeding events 
according to CYP2C19 genotype.
Our study has some limitations. Because it is observa-
tional in nature, in the case of poor and intermediate 
metabolisers, the investigator can use dual antiplatelet 
therapy (aspirin plus clopidogrel) or modify the clopido-
grel dose. Furthermore, it will be difficult to apply the 
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results of the study to western populations because only 
Asian patients will be included. Nevertheless, its strengths 
are that CYP2C19 genotype effects will be examined in a 
large sample and that it will reflect the real- world practice 
of stroke treatment.
Ethics and dissemination
The Institutional Review Board of Severance Hospital, 
Yonsei University College of Medicine, approved this 
study (approval reference number: 3-2019-0195). We have 
registered the study at  ClinicalTrials. gov (NCT04072705). 
Each institutional review board of the participating hospi-
tals approved the study (online supplementary file 1 
(ethics approval file) and online supplementary file 2 
(informed consent)). We plan to disseminate our find-
ings at relevant conferences and meetings and through 
peer- reviewed journals.
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